WO2006000222A3 - The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia - Google Patents

The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia Download PDF

Info

Publication number
WO2006000222A3
WO2006000222A3 PCT/DK2005/000422 DK2005000422W WO2006000222A3 WO 2006000222 A3 WO2006000222 A3 WO 2006000222A3 DK 2005000422 W DK2005000422 W DK 2005000422W WO 2006000222 A3 WO2006000222 A3 WO 2006000222A3
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
treatment
inhibitor
combination
antipsychotic
Prior art date
Application number
PCT/DK2005/000422
Other languages
French (fr)
Other versions
WO2006000222A2 (en
Inventor
Steffen Wad Joergensen
Allan Carsten Dahl
Michael Didriksen
Frank Larsen
Torbjoern Waerner
Karina Kroejer Soeby
Dorthe Bach Toft
Thomas Helboe
Original Assignee
Lundbeck & Co As H
Steffen Wad Joergensen
Allan Carsten Dahl
Michael Didriksen
Frank Larsen
Torbjoern Waerner
Karina Kroejer Soeby
Dorthe Bach Toft
Thomas Helboe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H, Steffen Wad Joergensen, Allan Carsten Dahl, Michael Didriksen, Frank Larsen, Torbjoern Waerner, Karina Kroejer Soeby, Dorthe Bach Toft, Thomas Helboe filed Critical Lundbeck & Co As H
Publication of WO2006000222A2 publication Critical patent/WO2006000222A2/en
Publication of WO2006000222A3 publication Critical patent/WO2006000222A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the combination of an antipsychotic agent selected from D2 receptor antagonists, partial agonists, or inverse agonists, and a glycine transporter type 1 (GlyT-1) inhibitor. Accordingly, the present invention relates to the treatment of patients with schizophrenia, in particular treatment of patients with positive symptoms and negative symptoms, and cognitive impairment in patients with schizophrenia.
PCT/DK2005/000422 2004-06-24 2005-06-23 The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia WO2006000222A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58307404P 2004-06-24 2004-06-24
DKPA200400987 2004-06-24
US60/583,074 2004-06-24
DKPA200400987 2004-06-24

Publications (2)

Publication Number Publication Date
WO2006000222A2 WO2006000222A2 (en) 2006-01-05
WO2006000222A3 true WO2006000222A3 (en) 2006-06-29

Family

ID=34970466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000422 WO2006000222A2 (en) 2004-06-24 2005-06-23 The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia

Country Status (1)

Country Link
WO (1) WO2006000222A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066121A2 (en) * 2004-12-16 2006-06-22 Janssen Pharmaceutica N.V. Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
JP2014527175A (en) * 2011-08-26 2014-10-09 エフ．ホフマン−ラ ロシュ アーゲー Method for predicting clinical utility in the treatment of mental development, neurological or neuropsychiatric disorders
US20180193283A1 (en) 2016-12-20 2018-07-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
MX2019007389A (en) 2016-12-20 2019-08-16 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene.
JP2020525545A (en) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー Transdermal therapeutic system containing asenapine and silicone-acrylic hybrid polymer
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837730A (en) * 1995-12-07 1998-11-17 Javitt; Daniel C. Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
WO2002008216A1 (en) * 2000-07-21 2002-01-31 H. Lundbeck A/S Novel compounds and their use as glycine transport inhibitors
WO2002022581A1 (en) * 2000-09-14 2002-03-21 Gliatech, Inc. Nitrogen-containing compounds and their use as glycine transport inhibitors
US20020183390A1 (en) * 1999-08-03 2002-12-05 Dr. Daniel Javitt D-serine transport antagonist for treating psychosis
WO2003053942A1 (en) * 2001-12-20 2003-07-03 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
WO2005049023A1 (en) * 2003-11-18 2005-06-02 Glaxo Group Limited Glyt1 transporter inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837730A (en) * 1995-12-07 1998-11-17 Javitt; Daniel C. Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
US20020183390A1 (en) * 1999-08-03 2002-12-05 Dr. Daniel Javitt D-serine transport antagonist for treating psychosis
WO2002008216A1 (en) * 2000-07-21 2002-01-31 H. Lundbeck A/S Novel compounds and their use as glycine transport inhibitors
WO2002022581A1 (en) * 2000-09-14 2002-03-21 Gliatech, Inc. Nitrogen-containing compounds and their use as glycine transport inhibitors
WO2003053942A1 (en) * 2001-12-20 2003-07-03 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
WO2005049023A1 (en) * 2003-11-18 2005-06-02 Glaxo Group Limited Glyt1 transporter inhibitors

Also Published As

Publication number Publication date
WO2006000222A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
WO2006000222A3 (en) The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
EP1461061A4 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2004047838A3 (en) Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents
HK1069767A1 (en) Methods for inhibiting ocular processes
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
MY143215A (en) Multifocal lenses for pre-presbyopic individuals
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
HRP20090245T1 (en) Pyy agonists and uses thereof
WO2005055951A3 (en) Methods and compositions for slowing aging
EP1199069A3 (en) Use of an estrogen agonist/antagonist for assessing, improving, or maintaining urogenital health
DE60227991D1 (en) GTEIL AND AUXILIARY MECHANISM FOR THE TURNING PROCESS
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
NO20053355L (en) Alpha-2 delta ligand to treat lower urinary tract symptoms.
MX2007005478A (en) Formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives.
WO2005117979A3 (en) Use of il-17 in the treatment of fertility-related disorders
WO2007053495A3 (en) Compounds useful as antagonists of ccr2
HUP0401485A2 (en) Pharmaceutical composition containing combination of selected opioids with muscarine antagonists for treating urinary incontinence
WO2006091861A3 (en) Compositions and methods relating to cns lymphoma
AU2003239280A1 (en) Combination treatment for depression and anxiety by nk1 and nk3 antagonists
ATE511512T1 (en) OLANZAPIN PAMOATE DIHYDRATE
WO2007053499A3 (en) Compounds useful as antagonists of ccr2
WO2003084384A3 (en) Diagnosis of flavivirus infection
WO2005042021A3 (en) Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
AU2003261001A8 (en) Composite electrode for electrochemical cod measurement
UA91988C2 (en) Pharmaceutical compositions based on nk2 antagonists for pediatric use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05750853

Country of ref document: EP

Kind code of ref document: A2